CD34 and acute myeloid leukemia: The link between chemoresistance and leukemic stemness is supported also by other observations, showing that: (i) CD34+/CD38− cell frequency predicts the outcome in adult AML [14]; (ii) the stem cell-associated signature allows risk stratification in pediatric AMLs [15] and (iii) the ERG+ enhancer region 85high stem cell marker is associated with resistance to chemo- and radiotherapy predicts AML outcome [16].